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with mutations in the HSD17B10 gene are unrelated to accumulation of toxic
metabolites in the isoleucine pathway and, rather, related to defects in general
mitochondrial function. Therefore alternative therapeutic approaches to an
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52INTRODUCTION
Organic acidurias are inherited metabolic disorders caused by
the deficiency of enzymes involved in the mitochondrial
oxidation of coenzyme A (CoA)-activated acyl compounds
derived from amino acid breakdown. Clinical symptoms
frequently develop at times of increased protein catabolism
due to fasting or illness, leading to increased flux through
oxidative pathways and accumulation of pathological metabo-
lites. We have previously reported a novel organic aciduria
caused by a deficiency of the mitochondrial enzyme 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase (MHBD) involved in iso-
leucine metabolism (Zschocke et al, 2000). The clinical picture
of this condition is very different from other organic acidurias.
Most of the affected children do not develop metabolic crises
and show few symptoms in the first year of life. From the second
year on they follow a neurodegenerative disease course
associated with mitochondrial dysfunction, leading to progres-
sive loss of skills, neurological abnormalities including epilepsy,
cardiomyopathy, retinal degeneration and death. The causative
HSD17B10 gene is located on the X-chromosome and encodes
17b-hydroxysteroid dehydrogenase type 10 (HSD17B10, abbre-
viated HSD10) (Ofman et al, 2003). Several studies have indi-
cated that this protein (also known as ERAB¼ endoplasmatic
reticulum-associated amyloid-b-binding protein, or ABAD¼
amyloid-b-binding alcohol dehydrogenase) binds amyloid-b
(Ab) and mediates mitochondrial toxicity in Alzheimer’s
disease (AD, Lustbader et al, 2004; Yan et al, 1997). HSD10
is thus implicated in two neurodegenerative disorders but the
pathogenetic basis has so far remained elusive.
Here we report that the severity of symptoms in patients with
MHBD deficiency (MHBDD) is not correlated with residual
enzyme activity of the mutated HSD10 proteins, suggesting that
the HSD10 protein has other functions in addition to the
enzymatic activity. In vertebrate systems, no loss-of-function
data are available for HSD10, so far. We present evidence in
Xenopus and mouse embryos, as well as in fibroblasts from
patients with MHBDD that HSD10 is required for structural and
functional integrity of the mitochondria. This function is
independent of the enzymatic activity of the protein. Rescue
experiments with wild type (WT) and mutant protein in
Xenopus embryos in which HSD10 function was knocked-down
revealed striking functional differences in properties of muta-
tions found in MHBDD patients. Mutation Q165H, associated
with complete loss of enzymatic activity but normal neurolo-
gical development in humans, prevented apoptosis induced by
HSD10 knock-down. In contrast, no rescue of the apoptosis
phenotype was observed with humanmutations associated with
classical disease presentation (R130C, up to 64% residual
enzyme activity) or a very severe clinical phenotype (D86G,
30% residual enzyme activity). These results were corroborated
by rescue experiments in dendritic cells derived from homo-
zygous HSD10 Tie2-Cre knock-out mice and indicated that the
enzymatic activity of HSD10 is not required for cell survival.
Our data indicate that loss of (non-enzymatic) HSD10
function mediated by gene mutation, knock-down or knock-
out causes mitochondrial dysfunction and apoptotic cell death. 2010 EMBO Molecular MedicineThese findings shed new light on the pathogenesis of the clinical
features of MHBDD and argue for new approaches to therapy.
They also may be of relevance to the understanding of
neurodegeneration in other conditions.RESULTS
Enzymatic activity of mutated HSD10 protein and severity of
symptoms in patients do not correlate
In order to gain insight into the pathogenesis of neurodegenera-
tion in MHBD deficiency and to obtain further information on
the biological role of HSD10, we investigated additional patients
with MHBDD. The condition was retrospectively diagnosed in
one child (case 1, Supporting Information) with a very severe
neonatal presentation, absent neurological development and
death from progressive hypertrophic cardiomyopathy at the age
of 7 months. MHBD activity in fibroblasts, as determined in two
independent laboratories, was only partially reduced to
approximately 30% of normal. This was considerably higher
than for other patients with MHBDD. Sequence analysis of
the complete coding region of the HSD17B10 gene in this
patient revealed hemizygosity for a novel mutation p.D86G
(c.257A>G) in exon 3; no other mutation was identified.
MHBDD was also diagnosed in a boy (case 2, Supporting
Information) who presented with pre- and postnatal failure
to thrive but normal cognitive and motor development.
Neurological examination in this boy and two affected relatives
(brother and cousin) has been entirely normal up to the present
age of 8 years. There was no measurable MHBD activity in
fibroblasts; molecular studies identified hemizygosity for the
novel mutation p.Q165H (c.495A>C) in exon 5 of theHSD17B10
gene.
Observations in these patients indicated that the development
and severity of symptoms in MHBDD is unrelated to residual
enzyme activity. In order to confirm these findings we carried
out in vitro expression analyses of WT HSD10 and the relevant
mutations R130C (the common mutation), D86G (associated
with a very severe clinical phenotype) and Q165H (associated
with normal development). WT and mutants were expressed as
stable, soluble proteins (Supporting Information Fig 1). Further
insights were gained through the 3D structure determination of
human HSD10 (Fig 1A, B), which crystallized in spacegroup
P3221 and was determined to high resolution (1.2 A˚; data
collection and refinement details in Supporting Information
Table 1). Kinetic constants were determined with different
substrates (Fig 1E, F). Kinetic parameters calculated for the WT
enzyme were in line with earlier data reported for this enzyme
(Shafqat et al, 2003). Residual dehydrogenase activities of 64
and 28% were measured for mutations R130C and D86G,
respectively; however, mutation R130C was unstable at room
temperature and steadily lost enzyme activity (Fig 1C). Protein
stability was assessed with and without NADþ or NADH
cofactor as a function of temperature by differential scanning
fluorimetry (Fig 1D). Cofactor binding of NADþ or NADH, as
reflected by increased thermal stability, was observed for both
WT and D86G. In contrast, mutation Q165H located at the activeEMBO Mol Med 2, 51–62 www.embomolmed.org
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Figure 1. Crystal structure, stability and activity of the HSD10 homotetramer and mitochondrial morphology in fibroblasts from MHBDD patients.
Crystal structure of HSD10. (A) Diagram of the homotetramer. A NADH cofactor is bound to one monomer. (B) Diagram of a HSD10 dimer with the location of
the mutations. The active centre is marked by the substrate in red.
C. Enzyme activity of HSD10 over time. Kcat/KM of HSD10 WT and mutations measured in a 30min interval; substrate 2-methyl-3-hydroxybutyryl-CoA.
D. Stability of HSD10 WT and mutations. Mean value of Tm determined by differential scanning fluorimetry (DSF)-experiments and standard deviation are
shown. Black column: no cofactor/substrate, grey column: cofactor NADþ, white column: cofactor NADH ( indicates significant cofactor binding).
E, F. Enzyme activity of HSD10 with different substrates. (E) Kcat/KM of HSD10mutations with hydroxybutyryl-CoA as substrate (WT enzyme is taken as 100%). (F)
Kcat/KM of HSD10 mutations with 2-methyl-3-hydroxybutyryl-CoA as substrate in relativity to the WT enzyme.
G–J. Mitochondrial staining in patient fibroblasts. 300 nM Mitotracker Green FM were used on cells fixed with 3.7% formaldehyde on coverslips and
mitochondria were visualized on a Perkin Elmer spinning disc confocal ERS-FRET on Nikon TE2000 inverted microscope. (G) Control, (H) R130C, (I) D86G, (J)
Q165H.
K. Fibroblasts were sectioned for electron microscopy. Pictures of 10–43 random systematically chosen visual fields were taken in a magnification of
11.5 103, scale bars: 100 nm. Mitochondria were classified into three groups (1—dense, dark; 2—loosely packed; 3—depleted cristae) with group 3 not
only being morphologically distinct but also characterized by smaller mitochondria. Total numbers per sample and an overview of the cells are given in
Supporting Information Fig 3.  Indicate significance at p< 0.0001,  gives significance at p¼0.0366–0.0857 adjusted for multiple comparisons within the
experiment compared to control fibroblasts. Normal human dermal fibroblasts served as controls.
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Figure 2. Mitochondrial morphology in brains of mice with a conditional
knock-out in noradrenergic neurons (DBH-Cre).
A. Brains from knock-out mice were Vibratome sectioned (50mm), the loci
coerulei, which could be identified by pigmentation, were dissected
and prepared for electron microscopy. Scale bar: 100mm.
B, C. Mitochondria were classified into three groups (1—dense, dark;
2—loosely packed/swollen cristae; 3—depleted cristae). Total numbers
per sample and an overview of the cells are given in Supporting
Information Fig 5. Sections of the cerebellum, which lacks noradrenergic
neurons, served as a control.  Indicates significance (p<0.0001) of
differences to the cerebellum.
Pictures of 33 random systematically chosen visual fields were taken in
a magnification of 11.5103, scale bars: 100 nm.
54centre of the enzyme showed neither residual activity nor
cofactor binding in our experimental settings. Inability of the
mutation Q165H to bind the cofactor indicates that regardless of
the substrate, no enzymatic reaction requiring NADH or NADþ
(all known reactions) will be sufficiently catalysed by this
mutant protein. WT and all mutations alike showed identical
mitochondrial distribution (data not shown). The lack of
correlation between disease severity and residual enzyme
activity in MHBDD patients thus is not due to misdirection of
intracellular transport or impaired mitochondrial localization of
mutated HSD10. Mitotracker staining revealed a filamentous
network-like structure of the mitochondria in WT cells and
fibroblasts carrying the Q165H mutation. Cells with the R130C
and D86G mutations showed punctate and fragmented mito-
chondrial organization (Fig 1G–J). Despite the differences in the
Mitotracker staining the amount of mitochondrial material is not
reduced in patient cells judged by the amount of mitochondrial
marker Grp75 protein and TOMM20 mRNA (Supporting
Information Fig 2). The amount of HSD10 transcripts was nearly
identical in the cells analysed (WT, R130C and Q165H). In
agreement with the finding that the R130C mutation is unstable
(Fig 1C) less HSD10 protein could be detected in fibroblasts
carrying this mutation (Supporting Information Fig 2).
Mutations D86G and R130C cause severe disruption of
mitochondrial morphology
Since HSD10 WT and mutations are localized to mitochondria
and patients with MHBDD show signs of mitochondrial
dysfunction, we analysed mitochondrial morphology by EM
in fibroblasts derived from patients compared with control
fibroblasts (Fig 1K and Supporting Information Fig 3). The
majority of mitochondria in control cells showed WT morphol-
ogy (dense, dark). Fibroblasts carrying the Q165H mutation
maintained WT morphology of 45% of the mitochondria,
30% displayed an intermediate phenotype with loosely packed
and/or swollen cristae and 27% showed depletion of cristae
and appeared ‘empty’ (for details, see Material and Methods).
In contrast, in cells carrying the D86G and R130C mutation 65–
85% of the mitochondria displayed an aberrant phenotype
(group 2 and 3). The EM analysis of mitochondria of HSD10
mutant human cells thus showed that HSD10 is required for
mitochondrial integrity. This function is not correlated with
residual enzyme activity.
Mitochondrial disintegration after conditional Hsd17b10
knock-out in mice
Since knock-out of Hsd17b10 in mice results in early embryonic
lethality at gastrula stages (B. Arnold, unpublished data), we
established two conditional Hsd17b10 knock-out mouse lines.
In one line, Hsd17b10 was eliminated in endothelial cells and
cells of the immune system by mating mice carrying a floxed
allele ofHsd17b10with a Tie2 promoter driven Cre recombinase
strain. These mice are viable and fertile, but have defects in
spleen and vasculature. The animals die rapidly around week
25. Supporting Information Fig 4 shows the recombination
efficiency in spleen cells and dendritic cells of Tie2-
CreHsd17b10 mice as an example.. 2010 EMBO Molecular MedicineTo generate the second conditional knock-out line, mice
carrying a floxed allele of Hsd17b10were mated with a DBH-Cre
line which eliminates the Hsd17b10 gene in noradrenergic
neurons. These mice are viable and fertile but die around
week 26.
In the central nervous system (CNS) the locus coeruleus
contains noradrenergic neurons and we set out to analyse the
morphology of the mitochondria in this region by EM in
conditional knock-out mice. In the loci coerulei of DBH-Cre
HSD10 deficient mice, almost 30% of the mitochondria showed
depletion of cristae and appeared ‘empty’, more than 50% of the
mitochondria were loosely packed and had swollen cristae,
while normal morphology (dense, dark) was only found in 20%
(Fig 2, Supporting Information Fig 5). In the cerebellum of theEMBO Mol Med 2, 51–62 www.embomolmed.org
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mitochondria had WT morphology, 40% displayed the inter-
mediate phenotype and only 10% appeared ‘empty’ andwithout
cristae. A similar picture was observed in the peripheral nervous
system (PNS). Mitochondria were morphologically severely
altered in superior cervical ganglia isolated from DBH-Cre
conditional knock-out mice (Supporting Information Figs 6 and
7). The EM analysis of two independent primary cell types
(neurons of the CNS and PNS) from Hsd17b10 DBH-Cre
conditional knock-out mice thus confirmed in a genetic system
that HSD10 is required for mitochondrial structural integrity in
the CNS and the PNS and that the observed changes in
mitochondria are cell type independent.
HSD10 knock-down in Xenopus impairs mitochondrial
integrity and induces apoptosis
In order to study HSD10 loss of function in early vertebrate
embryos we turned to Xenopus as an experimental model. We
cloned the Xenopus homologue of HSD10 (xHSD10) and
performed RT-PCR analysis, as well as whole mount in situ
hybridization during the first 3 days of embryonic development.
HSD10 mRNA is provided maternally, and zygotic HSD10
transcription was found from neurula stages onward (Support-
ing Information Fig 8). In Xenopus embryos, translation of
mRNAs can be specifically blocked by Morpholino (Mo)
antisense oligonucleotides. Two Mo antisense oligonucleotides
were designed to inhibit HSD10 mRNA translation. Mo5
0UTR
targeted the 50UTR and MoATG the coding region of xHSD10.
Both oligos specifically suppressed HSD10 translation in
Xenopus embryos (Fig 3A).Figure 3. Mitochondrial function and morphology in Xenopus animal caps.
A. Functionality and specificity of antisense Mo oligonucleotides is shown. An
Xenopus embryos. Protein extract from these embryos was subjected to Wes
can block the translation of 50xHSD10 cDNA including the 50UTR, but not the
translation of both constructs.
B. Effect of HSD10 knock-down onmitochondrial function. Animal caps were di
measured. Counts per minute (CPM) is shown in relation to uninjected con
C, D. Animal caps were dissected from injected Xenopus embryos and sectioned for
were taken in a magnification of 6.6 103, scale bars: 100 nm (C). Mitochond
depleted cristae) and the distribution is shown in (D).  Indicates significance
sample and an overview of the cells are given in Supporting Information F
www.embomolmed.org EMBO Mol Med 2, 51–62Next we tested whether HSD10 knock-down impaired
mitochondrial function. Antisense MoATG was microinjected
into the prospective ectoderm and the injected region (animal
cap) was explanted and cultured. Explanted animal caps
differentiate into a homogeneous tissue, the so-called atypical
epidermis. After 2 days in culture, when control embryos had
reached tailbud stage, pyruvate turnover was measured as a
parameter of mitochondrial function. MoATG-injected samples
displayed a 40% reduction in pyruvate turnover compared to
the uninjected or control Mo (MoCo) injected tissue. Impaired
mitochondrial function was specific because co-injection of a
human HSD10 expression construct which could not be blocked
by the HSD10 MoATG rescued pyruvate turnover almost to the
level of uninjected controls (Fig 3B).
EM analysis revealed that the morphology of mitochondria
in animal cap explants was changed after HSD10 knock-down
(Fig 3C, D, Supporting Information Fig 9). Mitochondria showed
severe reduction of cristae and a generally irregular shape. This
phenotype was rarely observed in uninjected samples or in
tissue in which the MoATG was injected together with a human
HSD10 expression construct. This set of experiments demon-
strated by LOF analysis that HSD10 is required for functional
and structural integrity of mitochondria.
Next we asked whether Mo-mediated HSD10 knock-down
would interfere with the establishment of the early body plan in
Xenopus embryos. HSD10 MoATG was injected into dorsal
animal (d/a) blastomeres at the four-cell stage and the embryos
were grown for 2 days until they had reached tailbud stages. The
progeny of the d/a blastomeres contributes mainly to neural
tissue and indeed we found reduced brain tissue and eyes intisense Mo oligonucleotides and Myc-tagged HSD10 cDNA were injected in
tern blot using 9E10 anti-Myc antibody. Antisense Mo oligonucleotide Mo5
0UTR
translation of ATGxHSD10 cDNA starting with the start codon. MoATG can block
ssected from injected Xenopus embryos and the turnover of 1-C14 pyruvate was
trol (100%) and the standard error is given.
electronmicroscopy. Pictures of 24 random systematically chosen visual fields
ria were classified into three groups (1—dense, dark; 2—loosely packed; 3—
at p< 0.0001 compared to uninjected control animal caps. Total numbers per
ig 9.
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Figure 4. Loss-of-function analysis of xHSD10 using Mo antisense oligonucleotides.
A. The phenotype of embryos injected with xHSD10 MoATG and its rescue with hHSD10 are shown. The injection of MoATG resulted in small or no eyes and
reduced anterior structures in 99% (n¼60) of the injected embryos compared with control embryos. Differences in pigmentation are due to slightly
differing developmental stages of the MoATG injected and the rescued embryo. Rescue of this phenotype was shown in two independent experiments
(n¼ 40) where 92% of the embryos were WT and only 8% showed the knock-down phenotype.
B, C. The reduction of forebrain and mid-/hindbrain tissue is shown by in situ hybridization of embryos injected with MoATG in comparison to uninjected controls
using BF1 and otx2 as a markers. Fourteen out of 15 embryos (otx2) and 13 out of 15 embryos (BF1), respectively, showed reduction of forebrain and mid-/
hindbrain tissue but brain patterning is not disturbed.
D. The increase of apoptosis after knock-down of xHSD10 is shown by TUNEL staining (arrowheads). Embryos were injected with HSD10MoATG on the right side
(R). The left side (L) served as an internal control.
56MoATG-injected embryos (Fig 4A). This phenotype was specific
because a human HSD10 expression construct which did not
harbour the Mo binding site completely rescued the eye and
brain defects. Despite the adverse effects of xHSD10 knock-
down on neural tissue, the anterior/posterior (a/p) patterning of
the brain was unaffected in these embryos. The spatial
expression patterns of the forebrain marker BF1 and the
fore-/midbrain marker otx2 were unchanged, but expression
levels were reduced in MoATG-injected embryos (Fig 4B, C).
Transferase dUTP nick end labelling (TUNEL) staining of
embryos which received the xHSD10 MoATG only into the right
side of the body showed enhanced apoptosis on the injected side
(Fig 4D, Supporting Information Fig 10). Selective targeting of
the Mo is possible in Xenopus embryos because the dorsal/
ventral and the left/right axes can be seen already at the four-cell
stage due to pigmentation differences of the animal blastomeres.
Induction of apoptosis after siRNA-mediated knock-down of
HSD10 was confirmed in human SHSY5Y cells (Supporting
Information Fig 11).
HSD10 MoATG-induced apoptosis could be rescued by
human HSD10 WT which also rescued the defects in neural
tissue (Fig 5). The mutated HSD10 proteins found in human 2010 EMBO Molecular Medicinepatients, however, showed remarkable differences in their
ability to rescue the apoptotic phenotype. The Q165Hmutation,
which has less than 3% residual enzymatic activity but was
identified in three neurologically normal boys, partially
rescued HSD10MoATG-induced apoptosis. In contrast, injection
of the mutations R130C and in particular D86G failed to rescue,
and instead further enhanced apoptosis. D86G has consider-
able residual enzyme activity despite being associated with a
very severe clinical phenotype. The inability of the R130C and
D86G mutants to rescue apoptosis was not due to protein
mislocalization. In human HeLa and Xenopus A6 cells WT and
all mutated proteins colocalized with mitochondria (data not
shown and Supporting Information Fig 12). Next we performed
rescue experiments using dendritic cells derived from Tie2-Cre
HSD10 mice. Loss of HSD10 induced apoptosis was detected
and quantified by TUNEL assay. In agreement with our
Xenopus data, WT HSD10 and the Q165H mutant, but not the
R130C and the D86G mutants, partially rescued apoptosis
(Fig 5, Supporting Information Fig 4).
These experiments demonstrate that loss of HSD10 results in
induction of apoptosis independent of the cell type and
organism. The rescue experiments furthermore show thatEMBO Mol Med 2, 51–62 www.embomolmed.org
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Figure 5. Quantitative analysis of the effect of HSD10 loss-of-function on the apoptosis rate and rescue.
A. Experimental scheme.
B. Quantification of TUNEL staining on the right (injected) side of tailbud stage embryos (NF St. 33/34) normalized against the left (control) side. The standard
error of four individual experiments (n¼ 45–52 embryos) is shown.  Denotes significance of mean difference from uninjected control at p< 0.0001.
C. Dendritic cells fromWT mice and mice with a conditional knock-out in endothelial cells and haematopoietic stem cells (Tie2) were transfected with plasmids
(pT-Rex-DEST30) bearing human HSD10 WT or mutations for 48 h before TUNEL assay was performed. The percentage of TUNEL positive cells of three
independent experiments and standard error are shown. Statistical significance () of difference from WT cells was determined at p< 0.0001. The increase in
apoptosis rate caused by HSD10 knock-down can be rescued by human HSD10 WT and the Q165H mutation but not by R130C and D86G cDNA.apoptosis after HSD10 loss of function is not dependent on the
enzymatic activity of HSD10, again arguing for a non-enzymatic
function of this protein which is required in mitochondria.DISCUSSION
MHBD deficiency causes an atypical organic aciduria
Mitochondrial dysfunction is a commonly observed feature of
primary disorders of mitochondrial intermediary metabolism
such as the classical organic acidurias. Neurological abnorm-
alities in these conditions are usually attributed to accumulation
of toxic substrates proximal to a specific enzymatic block,
causing secondary interference with energy metabolism.
Primary apoptotic nerve cell death is not a feature of organic
acidurias. Here we report that neurodegeneration in MHBDD, a
recently identified organic aciduria, is not due to loss of enzyme
activity and, presumably, the accumulation of toxic metabolites,
but rather involves a fundamentally different pathomechanism.
Although the respective enzyme, HSD10 has an important role
in mitochondrial metabolism, we show that the adverse effects
of its deficiency are primarily caused by a non-enzymatic effect
triggeringmitochondrial disintegration, apoptosis and cell death.
Several lines of evidence presented here support this view.
Measurements of enzymatic activity in patient fibroblasts
revealed that the R130C and D86G mutations associated withwww.embomolmed.org EMBO Mol Med 2, 51–62classical and neonatal neurodegenerative forms of MHBDD, had
up to 30% residual activity compared to the WT protein. In
contrast, the Q165H mutation that was identified in three
children with normal neurological development was associated
with less than 3% residual enzymatic activity. Thus the severity
of the clinical phenotype is not at all correlated with the
enzymatic activity of the mutated HSD10 proteins. We
subsequently set out to corroborate this observation with
experimental evidence. Mitochondrial integrity and cell viability
could be restored after HSD10 knock-down in Xenopus and in
conditional knock-out mice by Q165H mutant HSD10 protein,
but not by R130C or D86G. Complete loss of the HSD10 protein
in mouse embryos causes lethality at very early stages of
embryogenesis (day 5 p.f.). It is unlikely that the embryonic
lethality is due to the lack of enzyme activity, because it was
shown for defects in comparable metabolic enzymes that toxic
metabolites are efficiently eliminated by the placenta.
Additional clinical observations support our conclusions.
Attempts to improve the condition of MHBDD patients by a
restrictive diet that avoids accumulation of potentially toxic
precursor metabolites failed (unpublished data). Slow progres-
sive neurodegeneration without metabolic crises is atypical
for organic acidurias caused by defects in mitochondrial
intermediary metabolism, and deficiency of the enzyme
2-methylacetoacetyl-CoA thiolase, positioned immediately after
MHBD in the isoleucine pathway, causes accumulation of the 2010 EMBO Molecular Medicine 57
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58same metabolites in sometimes even higher concentrations but
is associated with a completely different disease picture
(episodic ketoacidosis, no neurodegeneration). In contrast to
most other metabolic disorders, no null mutations that
completely eliminate the protein have been identified in
MHBDD. Indeed, one particular mutation, R130C, is found in
more than half of cases and has usually occurred de novo in the
respective patients. There is no evidence that the corresponding
nucleotide change c.388C>T represents a hypermutable posi-
tion, raising the possibility that most other mutations in the
HSD17B10 gene are not observed because they are incompatible
with life. This again is highly unusual for organic acidurias that
usually manifest after birth only, since prenatally toxic
metabolites are removed via the placenta. Finally, a splicing
variant of the HSD17B10 gene that causes moderately reduced
production of normal HSD10 without significant loss of enzyme
activity and without production of an abnormal protein was
found to cause an unusual non-progressive syndrome of mild
mental retardation, choreoathetosis and abnormal behaviour
(Lenski et al, 2007).
HSD10 has a non-enzymatic, protective function in
mitochondria
Reduction or loss of HSD10 in Xenopus, mouse and humans has
adverse effects onmitochondrial integrity and leads to enhanced
apoptotic cell death and reduced viability. Thus, HSD10 may be
a component serving to protect mitochondria at times of
increased metabolic stress. This interpretation is compatible
with the observation that infections or other stress situations in
patients with MHBDD may trigger clinical deterioration. In
response to metabolic stress, HSD10 protein translocates from
the mitochondrial matrix to the inner mitochondrial membrane
and this might be important for maintaining mitochondrial
integrity as this is an essential site for assembly of the
mitochondrial membrane permeability transition pore (Tieu
et al, 2004, and unpublished own data). A protective effect of
overexpressed HSD10 under conditions of oxidative stress was
found in the setting of acute brain damage (Yan et al, 2000) and
in a mouse model of Parkinson disease (Tieu et al, 2004). It
appears plausible that interaction of HSD10 with an integral
protein of the mitochondrial membrane could mediate its
protective effect and is disturbed by altered HSD10 protein
structure due to specific mutations.
Cellular energy failure caused by mitochondrial dysfunction
is thought to play an important role in the development of AD,
and several studies indicated that this effect is caused by a direct
interaction of Ab with HSD10 (Lustbader et al, 2004; Yan et al,
1997). HSD10 protein or transcript was found to be increased in
affected neurons in human AD as well as in AD mouse models
and it has been suggested that overexpression of HSD10
amplifies Ab-mediated mitochondrial toxicity (Chen & Yan,
2007). However, a recent study showed that a mitochondrial
bioenergetic deficit precedes HSD10 overexpression and
Alzheimer’s pathology in an AD mouse model (Yao et al,
2009). The results of our present study, the first to examine the
effect of HSD10 loss-of-function, indicate that adverse effects
observed as a consequence of the binding of Ab to HSD10 are 2010 EMBO Molecular Medicinemore likely due to Ab-mediated loss of a non-enzymatic HSD10
function, and that increased amounts of (non-functional) HSD10
protein may be produced as a secondary or compensatory
mechanism. It thus remains possible that the mitochondrial
interaction of Ab with HSD10, triggering early dysfunction of
energy homeostasis, is one of the first steps in the pathogenesis
of AD.
Therapeutic implications
Our conclusion that toxic metabolites are not responsible for the
clinical symptoms observed in MHBDD patients implies that
treatment targeting reduction of precursor metabolites through
dietary measures is not indicated. This is in line with the clinical
observation that dietary reduction of the isoleucine load has no
beneficial effect on the course of this disease. In contrast,
treatment of patients with MHBDD should aim at reducing
mitochondrial stress and maintaining mitochondrial home-
ostasis through proactive management of infections and fever
and possibly the administration of vitamins and cofactors. Our
results may also contribute to a better understanding of
neurodegeneration in the context of AD. Strategies to reduce
Ab toxicity through inhibition of its interaction with HSD10
could make HSD10 an interesting protein for Alzheimer’s
therapy.MATERIALS AND METHODS
Enzymatic methods
Enzyme purification
Bl-21 DE3 cells (Invitrogen) were used for protein expression after
transformation with p11 expression vectors containing cDNA of
HSD10 WT or mutations. Bacteria were cultivated at 37 8C and
160 rpm until OD6001. Protein expression was induced with
0.5mM IPTG (Sigma) and continued overnight at 30 8C. Cells were
harvested for 15min at 6500 rpm (4 8C) and resuspended in binding
buffer (500mM NaCl, 5% glycerol, 50mM HEPES pH 7.5, 5mM
imidazole, 1mM PMSF, 0.5mM TCEP, protease inhibitor cocktail tablet,
EDTA free). Lysis of cells was achieved with an EmulsiFlex-C5 High
Pressure Homogenizer (Avestin). Cell debris was removed by
centrifugation (45min, 16 500 rpm, 4 8C) and the supernatant was
subjected to immobilized metal ion affinity chromatography. His-
tagged proteins were eluted from Ni2þ-sepharose (GE Healthcare)
with elution buffer containing 250mM imidazole. TEV protease
(Invitrogen) was used to remove His tags. HSD10 enzymes were
further purified by gelfiltration using HiLoadTM 16/60 Superdex 75
prep grade (GE Healthcare) and by ion exchange chromatography
using ‘Resource S’ and ‘Mono Q5/50GL’ (GE Healthcare). Enzyme
purification was evaluated by SDS-PAGE. Protein mass was deter-
mined by mass spectroscopy in an Agilent LC/MSD TOF.
Protein crystallization
Crystallization of HSD10 WT protein was performed by mixing
14.25mg/ml protein and crystallization solution (25.5% PEG3350,
0.17M (NH4)2SO4, 15% glycerol) in a 1:1 ratio at 48C in sitting drops.
Experiments were performed in the presence of 5mM NADH (Sigma).
Crystals were mounted directly from the crystallization solution andEMBO Mol Med 2, 51–62 www.embomolmed.org
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beamline SLS-X10 (SLS, Switzerland). The 3D structure of HSD10 was
determined to a resolution of 1.2 A˚ by molecular replacement with the
medium resolution structure of HSD10 as search model (PDB id 1u7t).
The structure was deposited with the ProteinDataBank under the
accession number 2023. Data collection and refinement statistics are
found in Supporting Information Table 1.
Enzyme kinetics
Different amounts of purified enzyme and substrate in the presence
of the cofactor NADþ (Sigma) (400mM in 100mM Tris/HCl pH 9, 25 8C)
were incubated in a SpectraMax M5/M5e Microplate Reader and the
change in nucleotide cofactor absorbance (A340nm) was measured.
Graph Pad Prism program was used to determine KM and Vmax.
Differential scanning fluorimetry (DSF)
Purified proteins (10mM) in HEPES buffer (10mM, pH 7.5) were
incubated with 150mM NaCl, 85mM substrate and 0.5ml SYPRO
Orange (Invitrogen) in the presence or absence of cofactors NADþ and
NADH (200mM). Fluorescent emission was measured in an Mx3005p
RT-PCR machine (Stratagene) and incubation temperature increased
from 25 to 758C (18C/min).
Mitochondrial function
Xenopus animal caps were homogenized in 500ml homogenization
buffer (250mM sucrose, 50mM KCl, 5mM MgCl2, 20mM Tris/HCl, pH
7.4) using a Potter-Elvehejm system and 7 downstrokes. The
suspension was incubated with 50ml 10mM malate and 50ml
1-C14 pyruvate (5mCi/ml, GE Healthcare) for 1 h at 378C in a
scintillation vial that contains a tube with 200ml hyamine. This tube
was transferred in a new scintillation vial containing 7ml UltimaGold
(Perkin Elmer) and measured in a scintillation counter.
Electron microscopy
Primary fixation was done with 2.5% glutaraldehyde in PBS. For easier
handling tissue culture cells were scraped off and embedded in 2%
agarose. All samples were postfixed with 1% osmium tetroxide (Serva
Electrophoresis) in 100mM phosphate buffer pH 7.2 for 1 h on ice,
washed extensively with water, block-stained with 1% aqueous uranyl
acetate (Serva Electrophoresis) for 1 h at 48C, dehydrated in a graded
series of ethanol at ambient temperature, infiltrated with mixtures of
ethanol/Epon and finally embedded in Epon. Ultrathin sections were
stained with uranyl acetate and lead citrate (Serva Electrophoresis)
(Venable & Coggeshall, 1965) and viewed in a Philips CM10 electron
microscope at 60 kV using a 30mm objective aperture. Mitochondria
were quantitatively classified into groups according to their morphol-
ogy by examiner who was blinded to the nature (WT/mutant, etc.) of
the samples. Group 1 is distinguished by a regular arrangement and
shape of the cristae stacks. Group 3 characteristics are a reduced
cristae compartment resulting in less electron dense material in the
mitochondria and an irregular arrangement and shape of the cristae
stacks. Group 2 is represented by an intermediate morphological
phenotype (see Figs 1K, 2B and 3C).
All samples were sectioned at random angles resulting in cross and
longitudinal sections of mitochondria. For the morphological analyses
the plain of sections was not relevant.www.embomolmed.org EMBO Mol Med 2, 51–62Statistical evaluation
For each mitochondrium the density was used as an ordinal variable
(dense, medium or depleted). The variable was evaluated as a
categorical variable within a logistic model framework. The hypothesis
of equal density distribution rates for different treatments was tested
controlling for a suitable covariante (animal cap, brain sections or
patient) in the respective experiment. All analyses have been
performed with SAS 9.1 on PC (SAS Institute, Inc., Cary, NC). Differences
were counted as significant if the p-values were lower than 5%
adjusted for multiple testing within one experiment.
Generation of a specific conditional HSD10 knock-out in
noradrenergic neurons and immune cells
As mice deficient for HSD10 display embryonic lethality, two conditional
knock-out mouse lines were generated. The construct used to
generate floxed HSD10 alleles contained the coding sequence for
HSD10 with exon 1 being flanked by loxP sites. This construct was
introduced into embryonic stem cells (E14.1 of the 129P2/Ola Hsd
stem) via electroporation. 20mg DNA were mixed with 107 cells in PBS
and electroporated at 240V and 960mF. Stable clones were selected
with G418 and cultured in DMEM containing LIF (myeloid leukemia
inhibitory factor) on a layer of Feeder cells. Blastocysts were gained from
pregnant C57Bl/6N mice at day 3.5 p.c. Stable transfected ES cells (20–
25) were injected into the blastocoel and the blastocysts were
transferred into pseudo-pregnant NMRI females at day 2.5 p.c. Resulting
chimeric male animals were backcrossed with C57Bl/6N females to
homozygosity.
To generate an Hsd17b10 DBH-Cre conditional knock-out mouse, a
transgenic mouse line carrying the Cre recombinase under the control of
the DBH promoter was mated with a mouse line carrying a floxed allele
of Hsd17b10. In the DBH-Cre line Hsd17b10 is eliminated specifically in
noradrenergic neurons of the peripheral and CNS. The generation of
DBH-Cre mice has been described previously (Stanke et al, 2006).
The second conditional knock-out (Hsd17b10 Tie2-Cre) in en-
dothelial cells and hematopoietic stem cells was achieved using a
transgenic mouse line carrying the Cre recombinase under the control
of the Tie2 promoter. Generation of these mice has been described
elsewhere (Constien et al, 2001).
Tissue preparation
Animals were killed and immediately dissected to collect brains.
Tissues were fixed in 4% formaldehyde, 1% glutaraldehyde in PBS and
cut in Vibratome sections (50mm). Appropriate regions of the brain
were identified by pigmentation and dissected from these Vibratome
sections prior to electron microscopy.
Isolation and cultivation of dendritic cells
Dendritic cells from WT and HSD10 knock-out mice were isolated
from bone marrow and expanded for 10 days in GM-CSF supple-
mented F1/16 medium. The ratio of CD11 positive cells used for the
experiments was measured by FACS analysis and varied between
70 and 90%.
Transfection
Dendritic cells were transfected with 0.5mg/106 cells plasmid-DNA
(pT-Rex-DEST30) coding for HSD10 WT or mutations, respectively by 2010 EMBO Molecular Medicine 59
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The paper explained
PROBLEM:
HSD10 is an essential enzyme in the isoleucine breakdown
pathway and has also been reported as an important mediator of
mitochondrial toxicity in Alzheimer’s disease. A deficiency of
HSD10 caused by mutations in the HSD17B10 gene can be
recognized by specific metabolic changes. However, children
with HSD10 deficiency show a neurodegenerative disease picture
that does not resemble other disorders of isoleucine metabolism
or similar organic acidurias but is more reminiscent of primary
mitochondrial disorders. The exact pathomechanism is unknown.
RESULTS:
By investigating additional patients with a genetic deficiency of
HSD10 we show that there is no correlation between enzyme
activity and clinical presentation. Loss-of-function and rescue
experiments in Xenopus embryos and cells derived from
conditional Hsd17b10/ mice demonstrate that HSD10 is
essential for structural and functional integrity of mitochondria
independently of its enzymatic activity. Impairment of this
function in neural cells causes apoptotic cell death whilst the
enzymatic activity of HSD10 is not required for cell survival.
IMPACT:
The exact molecular mechanisms leading to mitochondrial
disintegration and neuronal apoptosis in HSD10 deficiency are
still unknown but our data show that the clinical effects cannot
be attributed to the accumulation of toxic metabolites in the
isoleucine pathway or othermetabolic effects. Rather, HSD10 has
a protective effect on mitochondrial integrity. Delineation of this
protective mechanism should provide new therapeutic
perspectives for HSD10 dysfunction. Children with a genetic
deficiency of HSD10 are unlikely to benefit from an
isoleucine-restricted diet, previously suggested as a therapeutic
option. Treatment should aim at reducing mitochondrial stress
and maintaining mitochondrial homeostasis through proactive
management of infections and fever and possibly the
administration of vitamins and cofactors.
60electroporation (Microporator MP-100, Peqlab) using single pulses of
990 V for 40ms. Transfection efficiency was confirmed by PCR for the
neomycin-gene on pT-Rex-DEST30.
TUNEL assay
TUNEL assay was performed 48h after transfection using the In Situ Cell
Death Detection TMR kit (Roche). The staining was performed according
to the manufacturer’s instructions. The cells were counterstained with
DAPI nuclear stain (Vector Laboratories) and evaluated with an Olympus
AX70 microscope. TUNEL-positive cells were counted in five different
visual fields using the visualizing software Cell F (Olympus) and
expressed as the percentage of positive cells. Rates in apoptotic cells for
different transfections were compared to WT cells by a Chi-square test.
Differences were counted as significant if the p-values were lower than
5% adjusted for multiple testing within one experiment.
Embryological methods
Eggs were obtained by injecting human chorionic gonadotropin
(Sigma) into female Xenopus laevis and fertilized artificially. Embryos
were dejellied using 2% L-cysteine (pH 7.8–8.0, Biomol) and cultured
in 0.1 MBSH. Embryo stages were determined according to
Nieuwkoop and Faber (1967). Animal caps were dissected at stage
8 or 9 and cultured in 0.5 MBSH until stage NF 33/34.
Gene knock-down
For the specific knock-down of HSD10 in Xenopus embryos the
following two Mo antisense oligonucleotides (Gene Tools) were used:
Mo5
0UTR 50tgaccaaccaattgcagtcattcat30 and MoATG 50ccttcaggttcctca-
catgcgccat30 binding the 50UTR and the region of the start codon of
HSD10 mRNA, respectively. Control Morpholino MoCo 50cctcttacctca-
gttacaatttata30 was used as an inert control. 2010 EMBO Molecular MedicineGene overexpression
The following DNA constructs were used in rescue experiments: pT-
Rex-DEST30 containing cDNA of hHSD10 and the mutations R130C,
D86G and Q165H. Constructs were obtained by cloning using
Gateway Technology (Invitrogen). Other constructs were pCS2þ_myc
containing xHSD10 and xHSD10 including the 50UTR.
Microinjection
Embryos were cultured in 1 MBSH (88mM NaCl, 1mM KCl, 2.4mM
NaHCO3, 0.82mM MgSO47H2O, 0.41mM CaCl22H2O, 0.33mM
Ca(NO3)4H2O, 10mM HEPES, pH 7.5) for microinjection and
injected with 5 nl of diluted Mo or DNA into each blastomere.
Protein extract
Xenopus embryos were lysed in RIPA buffer (20mM Tris/HCl pH 7.5,
0.1% NP-40, 10% glycerol, 10% protease inhibitor tablets), cell
debris was pelleted for 5min at 2300 g, and the protein fraction
was mixed well with 1 volume Freon (Fluka). The protein suspension
was obtained by centrifugation for 5min at 2300 g. Protein
samples were analysed by SDS-PAGE and Western Blot using 9E10
anti-Myc antibody (Merck) to detect overexpressed xHSD10_myc
protein.
In situ hybridization
Embryos of different stages were fixed in MEMFA (100mM MOPS,
2mM EGTA, 1mM MgSO4, 3.7% formaldehyde), and stored in
methanol at 20 8C. Whole-mount in situ hybridization was
performed according to Harland, 1991. DIG-labelled antisense RNA
was synthesized using Digoxygenin RNA labelling Kit (Roche) with
pCS2þ/otx2 and pBluescriptSKþ/xBF1 digested with BamHI and XbaI
as a template.EMBO Mol Med 2, 51–62 www.embomolmed.org
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Embryos were fixed in MEMFA for terminal deoxynucleotidyl TUNEL
analysis and stored in methanol at 208C. The whole-mount staining
protocol was previously described (Hensey & Gautier, 1997). Statistical
evaluation of the significance of the rescue experiment was achieved
by comparing the differences in the amount of apoptosis spots on the
injected side of the embryo with the uninjected side within an one
way analysis of variance and Scheffe test was used for post hoc
pairwise group comparisons. Differences were counted as significant if
the p-values were lower than 5% adjusted for multiple testing within
one experiment.
Cell culture methods
Fibroblasts from MHBDD patients and control fibroblasts were
cultivated in DMEM ReadyMix (Paa Laboratories) at 378C and 5%
CO2. Mitochondrial staining in patient fibroblasts was achieved within
20min with 300nM Mitotracker Green FM (Invitrogen) on cells fixed
with 3.7% formaldehyde on coverslips. Mitochondria were visualized
after mounting in Mowiol (Merck) on a Perkin Elmer spinning disc
confocal ERS-FRET on Nikon TE2000 inverted microscope.
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